相关实验视频

Updated: Jan 7, 2026

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Published on: January 7, 2022

对Muraymycin A1及其类似物作为DPAGT1抑制剂的新见解

Katsuhiko Mitachi¹, Deidre Daria², Jacob M Kirsh³

¹Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, Memphis, TN 38163, United States of America.

Bioorganic chemistry

|December 25, 2025

概括

穆雷米辛A1 (MA1) 选择性地抑制DPAGT1,显示对乳腺癌细胞的抗癌活性,同时保护正常细胞. 合成类型证实了这种向细胞毒性的结构要求.

科学领域:

生物化学生化学
药用化学医学化学
癌症生物学癌症生物学

背景情况:

穆雷米辛A1 (MA1) 是一种核类抗生素,可以抑制多利基酸N-乙烯基葡萄糖胺转化酶1 (DPAGT1).
细胞毒性作用和MA1活动的结构要求以前尚不清楚.
DPAGT1是N-糖基化途径中的关键酶,与癌症进展有关.

研究的目的:

合成Muraymycin A1 (MA1) 和它的类似物,以研究DPAGT1抑制的结构-活性关系.
评估MA1及其衍生物对癌细胞的选择性细胞毒性.
建立MA1作为一种生物化学工具,用于研究癌症中的N-糖化.

主要方法:

总合成MA1和关键类似物 (MA1-NH2,MA1-NH2-瓜尼迪尔).
酶抑制试验量化DPAGT1抑制功效.
使用乳腺癌细胞系 (包括三阴性细胞) 和正常细胞进行细胞增殖测定.

主要成果:

合成MA1是一种比tunicamycin V更强大的DPAGT1抑制剂.
MA1对乳腺癌细胞具有选择性的抗增殖活性,包括三阴性亚型,对正常细胞的毒性最小.
MA1类似物显示出可比的酶抑制和选择性细胞毒性,验证了已识别的结构要求.

结论:

已经确定了MA1对DPAGT1抑制必不可少的最小结构特征.
MA1及其类型在固体瘤中的N-糖化研究中作为有价值的,有选择性的生物化学工具.
这些发现为开发新的向抗癌疗法提供了基础.

关键词:

反移民活动是反移民活动.反扩散活动的反扩散活动.DPAGT1 抑制剂的使用使用MraY/MurX抑制剂.在Muraymycin A1中使用.穆雷米辛A1类型的类似物.在N-Glycan生物合成过程中.PNPT PNPT 这是一个很好的方法.总的合成总的合成.图尼卡胺基因是什么

更多相关视频

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

相关概念视频

Antimicrobial Proteins

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...